The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are ...

Rabat - A scientific breakthrough has just been achieved in Morocco, marked by the publication of the findings from the first ...

We Care About Your Privacy By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Writing in Molecular Therapy Nucleic Acids, researchers hypothesized that using poly(A) tail mimetics to enhance mRNA expression from haploinsufficiency-associated genes could be a disease-modifying ...

Patients with Fuchs endothelial corneal dystrophy with particular genetic markers are at higher risk for surgery and vision loss.

The colt was fittingly named Im A Standardbred. As Dave Little reported in his Meadowlands media release about Always B ...

Using genetically predicted metabolic reaction fluxes, the authors identify reactions that can amplify or buffer the effect ...

Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, along with blood biomarker and neuroimaging outcomes. Baseline demographics, ...

Brian Tait, Chief Scientific Officer at Haplomic Technologies Pty Ltd, focuses here on CYP genes, haplotypes, and their ...

Douglas A. Tremblay, MD, discusses the long-term data supporting ropeginterferon alfa-2b-njft as treatment in patients with polycythemia vera.

A recent study released by the University of Wisconsin-Madison sheds light on how the sugary enhancer1 (se1) allele influences the nutritional profile ...